EVOMMUNE INC

EVMNNYSE

🏆 #2409 by market capEarnings Oct 16US Equity

$14.21▲ $0.14 (+1.00%)

🌙 After hours$14.00▼ 1.48%Regular close · extended-hours price shown

1h—

24h▲ 1.0%

7d▲ 9.5%

14d▲ 28.5%

30d▲ 17.4%

1y—

🏦Market Cap

$516M

Small Cap

📈Revenue Growth (YoY)

+85.7%

High Growth

📊Gross Margin

96.5%

High

💵FCF Margin

-746.5%

Thin

⚖️P/S Ratio

51.6x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $14.03 – $14.43
52-Week Range: $10.47 – $33.20
Volume: $2.64B
Avg Volume: $2.53B
Shares Outstanding: 36.3M
Next Earnings: Oct 29, 2026

Fundamentals Snapshot

Annual Revenue: $13M
Last Q Revenue: $4M
P/E Ratio: -5.0
P/S Ratio: 51.6x
EPS (TTM): $-2.62
Dividend Yield: 0.00%

Why Investors Own EVMN

✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
✓Healthy economics — 47% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$13M▲ +17.3% YoY

Gross Margin (TTM)

47.4%▲ +2.9% YoY

Operating Income (TTM)

$1M▲ +17.3% YoY

Free Cash Flow (TTM)

$1M▲ +17.3% YoY

About EVOMMUNE INC

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

🦦